Why full FDA approval of the Pfizer vaccine wasn't the 'silver bullet' for vaccination rates

Pop-up vaccine clinic sign.
(Image credit: Justin Sullivan/Getty Images)

Even though health officials had hoped the opposite to be true, a federal government analysis suggests full FDA approval of Pfizer's COVID-19 vaccine had only a "modest and relatively short-lived" effect on vaccination rates, CNN reports. In other words, while there was a resulting uptick, full licensure was not the "silver bullet" to completely eliminate vaccine hesitancy.

"There weren't suddenly lines around the block," said Becca Siegel, a senior adviser to the U.S. Department of Health and Human Services. That's because for "truly undecided people, this is a complex decision. It's not one thing," Siegel explained.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Brigid Kennedy

Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.